The stock price of Cyclacel Pharmaceuticals is likely to experience a short-term decline as a direct result of the reported earnings miss for Q3. Earnings reports are critical events that can significantly influence investor sentiment and stock valuation. The worse-than-expected EPS indicates potential underlying issues with the company's profitability or performance, which can lead to a loss of investor confidence and a decrease in stock price.